Alembic Pharma gets USFDA’s nod for Tizanidine Hydrochloride Capsules

15 Jan 2020 Evaluate

Alembic Pharmaceuticals (Alembic) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tizanidine Hydrochloride Capsules, 2 mg, 4 mg, and 6 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Zanaflex Capsules, 2 mg, 4 mg, and 6 mg, of Covis Pharma B.V. Tizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the management of spasticity.

Tizanidine Hydrochloride Capsules, 2 mg, 4 mg, and 6 mg have an estimated market size of $ 28 million for twelve months ending September 2019 according to IQVIA.

The company has a cumulative total of 111 ANDA approvals (99 final approvals and 12 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

649.65 -27.40 (-4.05%)
23-Mar-2026 15:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1759.90
Dr. Reddys Lab 1251.65
Cipla 1223.00
Zydus Lifesciences 860.35
Lupin 2297.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×